The structural safety of prototype transport and storage containers for very low-level radioactive liquid waste was experimentally estimated for its localization development. Transport containers for radioactive liquid waste have been researched and developed, however, there are no standardized commercial containers for very low-level radioactive waste in Korea. In this study, the structural safety of the designated IP-2 type container capable of transporting and temporarily storing large amounts of very low-level liquid waste, which is generated during the operation and decommissioning of nuclear power plants, was demonstrated. The stacking and drop tests, which were conducted to determine the structural integrity of the container, verified that there was no external leakage of the contents in spite of its structural deformation due to the drop impact. This study shows the effort required for the localization of the technology used in manufacturing transport and storage containers for very low-level radioactive liquid waste, and the additional structural reinforcement of the container in which the commercial intermediate bulk container (IBC) external frame was coupled.

Functional dyspepsia (FD) is a gastrointestinal disorder with diverse symptoms but no structural or organic manifestations. Benachio-F® (herein named ‘BF-1’) is an over-the-counter liquid digestive formulated with multiple herbal extracts, which has been reported to improve symptoms of FD. A total two experiments were conducted. First, we examined whether BF-1 can modulate the progression of FD through two experimental rat models. A total of three doses (0.3x, 1x, 3x of the human equivalent dose) were used. In the gastric emptying model, both 1x (standard) or 3x (3-fold-concentrated) BF-1 enhanced gastric emptying was compared with that of vehicle-treated animals. In a feeding inhibition model induced by acute restraint stress, treatment with 1x or 3x BF-1 led to a similar degree of restoration in food intake that was comparable to that of acotiamide-treated animals. Among the constituents of BF, fennel is known for its choleretic effect. Thus, we next investigated whether a novel BF-based formula (named ‘BF-2’) that contains an increased amount of fennel extract (3.5-fold over BF-1), has greater potency in increasing bile flow. BF-2 showed a superior choleretic effect compared to BF-1. Furthermore, the postprandial concentration of serum secretin was higher in animals pretreated with BF-2 than in those pretreated with BF-1, suggesting that the increased choleretic effect of BF-2 is related to secretin production. Our results demonstrate that BF-1 can modulate the pathophysiological mechanisms of FD by exerting prokinetic and stress-relieving effects, and that BF-2 has a better choleretic effect than BF-1.